Schweizer J, Kaulen R, Nierade A, Altmann E
2. Medizinische Klinik, Klinikum Dresden-Friedrichstadt.
Vasa. 1997;26(1):43-6.
The effect of 6 months' administration of celiprolol, atenolol and isosorbide dinitrate on peripheral arterial occlusive disease (PAOD), double-blind and placebo-controlled, was investigated in 56 patients with chronic ischaemic heart disease and stage IIb PAOD, using as criteria the walking distance and the change in resistance index in the femoral artery. The placebo group consisted of 14 patients with chronic ischaemic heart disease and the same stage of PAOD.
Patients on 50 mg/day atenolol showed a significant reduction in both pain-free and maximal walking range compared with the controls. In contrast, those taking 200 mg/day celiprolol and those on 80 mg/day isosorbide dinitrate demonstrated significant increases in pain-free and maximal, walking distance compared with the control group. The colour duplex sonographically measured Doppler flow through the femoral artery showed a significant decrease both in the patients taking celiprolol and in those on isosorbide dinitrate, while in those receiving atenolol the resistance index increased significantly.
The study shows that the beta-adrenoceptor blocker celiprolol also possesses a nitrate-like vasodilatory property and can be used in patients with chronic ischaemic heart disease and impaired peripheral arterial blood flow.
在56例患有慢性缺血性心脏病且处于IIb期外周动脉闭塞性疾病(PAOD)的患者中,采用双盲、安慰剂对照的方法,研究了为期6个月的塞利洛尔、阿替洛尔和硝酸异山梨酯对PAOD的影响,以行走距离和股动脉阻力指数的变化作为评判标准。安慰剂组由14例患有慢性缺血性心脏病且处于相同PAOD阶段的患者组成。
与对照组相比,服用50mg/天阿替洛尔的患者无痛行走范围和最大行走范围均显著降低。相比之下,服用200mg/天塞利洛尔的患者和服用80mg/天硝酸异山梨酯的患者与对照组相比,无痛和最大行走距离均显著增加。彩色双功能超声测量的股动脉多普勒血流显示,服用塞利洛尔的患者和服用硝酸异山梨酯的患者血流均显著减少,而服用阿替洛尔的患者阻力指数显著增加。
该研究表明,β-肾上腺素受体阻滞剂塞利洛尔也具有类似硝酸盐的血管舒张特性,可用于患有慢性缺血性心脏病和外周动脉血流受损的患者。